Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Giredestrant in grade 1 endometrial cancer
2023-504091-23-00Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of giredestrant in endometrial cancer (EC), sponsored by Roche. Primary endpoints: Regression rate at Month 6 and Adverse events. Started Mar 2023; status: completed.
02
Drugs
giredestrant
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2023-504091-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504091-23-00.